Physician profile
Christine A Sinclair
NPI 1457642688
$2,909.01
in general payments reported to CMS, 2019-2025
17 companies · $563 in 2025
The $563 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.47 · 2022: $72.92 · 2023: $1,347 · 2024: $897 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $466.08 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $319.27 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $299.78 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $289.88 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $189.81 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Corium, LLC | $188.74 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $186.60 | 2023-2025 | Trintellix |
| Lundbeck LLC | $163.10 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $153.65 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $153.37 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $122.86 | 2022-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $109.82 | 2023 | Qelbree |
| Indivior INC. | $87.32 | 2023-2024 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $55.90 | 2023-2025 | Ingrezza |
| Merck Sharp & Dohme LLC | $43.94 | 2023 | Belsomra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.32 | 2023-2024 | Caplyta |
| Harmony Biosciences LLC | $38.57 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.